

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6174999

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CELGENE CORPORATION	11/21/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	AMGEN INC.
<b>Street Address:</b>	ONE AMGEN CENTER DRIVE
<b>City:</b>	THOUSAND OAKS
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	91320-1799
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16805196
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)474-0448
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	312.474.6300
<b>Email:</b>	Docket@marshallip.com
<b>Correspondent Name:</b>	YULIYA VASILYEVA
<b>Address Line 1:</b>	233 SOUTH WACKER DRIVE
<b>Address Line 2:</b>	6300 WILLIS TOWER
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60606
<b>ATTORNEY DOCKET NUMBER:</b>	32328/40102U/US
<b>NAME OF SUBMITTER:</b>	DEREK W. BARNETT
<b>SIGNATURE:</b>	/Derek W. Barnett/
<b>DATE SIGNED:</b>	06/26/2020
<b>Total Attachments: 18</b>	
source=DOCS-#6089698-v1-Celgene_to_Amgen_Assignment#page1.tif	
source=DOCS-#6089698-v1-Celgene_to_Amgen_Assignment#page2.tif	
source=DOCS-#6089698-v1-Celgene_to_Amgen_Assignment#page3.tif	
source=DOCS-#6089698-v1-Celgene_to_Amgen_Assignment#page4.tif	
source=DOCS-#6089698-v1-Celgene_to_Amgen_Assignment#page5.tif	

source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page6.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page7.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page8.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page9.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page10.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page11.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page12.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page13.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page14.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page15.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page16.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page17.tif  
source=DOCS-#6089698-v1-Celgene\_to\_Amgen\_Assignment#page18.tif

## IP ASSIGNMENT AGREEMENT

**THIS IP ASSIGNMENT AGREEMENT** (this "Assignment") dated as of November 21 (the "Effective Date"), is made by and between Celgene Corporation, a Delaware corporation, ("Seller") and the Asset Selling Entities set forth on the signature page attached hereto (each, together with Seller, individually and collectively, as applicable, "Assignor"), Amgen Inc., a Delaware corporation ("U.S. Purchaser"), and Amgen (Europe) GmbH, a Swiss Gesellschaft mit beschränkter Haftung ("Swiss Purchaser," and together with U.S. Purchaser, each individually and collectively, as applicable, "Purchaser") (each of Assignor, on the one hand, and Purchaser, on the other hand, a "Party," and together, the "Parties").

### RECITALS

**WHEREAS**, pursuant to the Asset Purchase Agreement, dated as of August 25, 2019 by and between Seller and U.S. Purchaser (the "Asset Purchase Agreement"), Seller has agreed to sell and transfer, and to cause each of the Asset Selling Entities to sell and transfer, and Purchaser has agreed to purchase and accept from Seller, among other things, the Transferred IP such that (a) Swiss Purchaser acquires all of Assignor's and its respective Affiliates' right, title and interest in and to the Transferred IP (including Transferred Product Technology) existing under the Laws of any jurisdiction that is outside of the United States, including the Transferred Patents, Transferred Trademarks, and Transferred Copyrights set forth on Schedule A (such Transferred IP described in this clause (a), collectively, "Non-U.S. Transferred IP"), and (b) U.S. Purchaser acquires all of Assignor's and its respective Affiliates' right, title and interest in and to the Transferred IP (including Transferred Product Technology) that is not Non-U.S. Transferred IP, including the Transferred Patents, Transferred Trademarks, Transferred Copyrights and Transferred Domain Names set forth on Schedule B (such Transferred IP described in this clause (b), collectively, "U.S. Transferred IP");

**WHEREAS**, (a) Celgene International II Sàrl ("CIS II"), an Affiliate of Assignor, has appointed Seller as its agent to act in the name and on behalf of CIS II to assign CIS II's rights with respect to certain U.S. Transferred IP to U.S. Purchaser and to assign CIS II's rights with respect to certain Non-U.S. Transferred IP to Swiss Purchaser hereunder; and (b) Signal Pharmaceuticals, LLC ("Signal"), an Affiliate of Assignor, has appointed Seller as its agent to act in the name and on behalf of Signal to assign Signal's rights with respect to certain U.S. Transferred IP to U.S. Purchaser hereunder; and

**WHEREAS**, this Agreement is the IP Assignment Agreement referred to in the Asset Purchase Agreement and, as a condition to the Closing under the Asset Purchase Agreement, the Parties have agreed to enter into this Agreement.

**NOW, THEREFORE**, in consideration of the mutual promises hereinafter set forth and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree as follows:

1. Definitions. Capitalized terms used but not defined in this Assignment have the means ascribed to them in the Asset Purchase Agreement.

2. Assignment. Assignor, on behalf of itself and its Affiliates, hereby sells, assigns, conveys and transfers to (a) Swiss Purchaser, and Swiss Purchaser hereby accepts the sale, assignment, conveyance and transfer from Assignor of, all of Assignor's and its respective Affiliates' rights, title and interest in and to the Non-U.S. Transferred IP, including the Non-U.S. Transferred IP set forth on Schedule A, and all goodwill associated therewith, and (b) U.S. Purchaser, and U.S. Purchaser hereby accepts the sale, assignment, conveyance and transfer from Assignor of, all of Assignor's and its respective Affiliates' rights, title and interest in and to the U.S. Transferred IP, including the U.S. Transferred IP set forth on Schedule B, and all goodwill associated therewith, in each case, for the respective Purchaser's own use and enjoyment, and for the use and enjoyment of the respective Purchaser's successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by the Assignor (or, as applicable, its or their respective Affiliates) if this Assignment and sale had not been made, together with all rights of priority and renewals, and all income, royalties or payments due or payable as of the Effective Date or thereafter, and all past, present and future claims, counterclaims, credits, causes of action, rights of recovery and rights of setoff against third persons for infringement or other violation of the applicable Transferred IP, together with the right to sue for and collect any resulting recovery of damages, lost profits, legal fees and costs, including from acts which may have occurred prior to the Effective Date for the respective Purchaser's own use and enjoyment and for the use and enjoyment of its successors, assigns or other legal representatives (collectively, the "Assigned Rights").

3. Recordation. Assignor hereby authorizes and requests the relevant officials of the United States Patent & Trademark Office, the United States Copyright Office, and their respective counterparts in any applicable jurisdiction in the world, to take all necessary actions to record and otherwise perfect this Assignment and the transactions described hereunder.

4. Further Assurances. Assignor shall provide to Purchaser, its successors, assigns or other legal representatives, cooperation and assistance, as may be reasonably requested by Purchaser and at Purchaser's cost and expense (including, without limitation, the execution and delivery of any and all affidavits, declarations, oaths, samples, exhibits, specimens and other documentation as may be reasonably required): (i) in the preparation and prosecution of any application for registration of the Assigned Rights; (ii) in the prosecution or defense of any interference, opposition, cancellation, infringement or other proceedings that may arise in connection with any of the Assigned Rights, including, without limitation, testifying as to any facts relating to the Assigned Rights assigned herein and this Assignment; and (iii) in the implementation or perfection of this Assignment.

5. Governing Law. This Agreement, and all Actions based upon, arising out of or related to this Agreement or the transactions contemplated hereby, shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law rules or principles that would result in the application of the law of any other state.


6. Counterparts. This Assignment may be executed in one or more counterparts, and by either of the Parties in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Assignment by

facsimile or e-mail shall be as effective as delivery of a manually executed counterpart of this Assignment.

*[Remainder of this page intentionally left blank]*

**IN WITNESS WHEREOF**, each Assignor and Purchaser have duly executed this Agreement as of the date first written above.

**CELGENE CORPORATION**

By:   
Name: Matthew Roden  
Title: President

*[Signature page to Intellectual Property Assignment Agreement]*

AMGEN INC.



By: \_\_\_\_\_

Name: Jonathan P. Graham

Title: EVP, General Counsel & Secretary

AMGEN (EUROPE) GmbH

By: \_\_\_\_\_

Name: Justin G. Claeys

Title: Director

[Signature Page to IP Assignment Agreement]

**PATENT**  
**REEL: 053061 FRAME: 0396**

**Schedule B  
U.S. Transferred IP**

**U.S. Patents and Patent Applications**

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee/PTO Record	Title
13/010,738	US	1/20/2011	2011-0124645 A1	5/26/2011	8158672	4/17/2012	Granted	Celgene Corporation	FLUROALKOXY-SUBSTITUTED 1,3-DIHYDROISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES
10/748,085	US	12/29/2003	204448	10/14/2004	7173058	2/6/2007	Abandoned	Celgene Corporation	FLUROALKOXY-SUBSTITUTED 1,3-DIHYDROISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES
11/601,355	US	11/16/2006	2007-0072902	3/29/2007	7504427	3/17/2009	Granted	Celgene Corporation	FLUROALKOXY-SUBSTITUTED 1,3-DIHYDROISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES
12/363,664	US	1/30/2009	2009-0143382- A1	6/4/2009	7893102	2/22/2011	Abandoned	Celgene Corporation	FLUROALKOXY-SUBSTITUTED 1,3-DIHYDROISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES
60/366515	US	3/20/2002					Inactive	Celgene Corporation	(+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF
60/366516	US	3/20/2002					Inactive	Celgene Corporation	(+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF



Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
60/438450	US	1/7/2003					Inactive	Celgene Corporation	(+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF
15/016856	US	2/5/2016	2016-0151331	6/2/2016	9724330	8/8/2017	Granted	Celgene Corporation	METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE
12/945800	US	11/12/2010	2011-0112307 A1	5/12/2011	8093283	1/10/2012	Granted	Celgene Corporation	SOLID FORMS COMPRISING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE, COMPOSITIONS THEREOF, AND USES THEREOF
10/392195	US	3/19/2003	2003-0187052	10/2/2003	6962940	11/8/2005	Granted	Celgene Corporation	(+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF
13/682652	US	11/20/2012	2014-0024695	1/23/2014	8802717	8/12/2014	Granted	Celgene Corporation	METHODS OF TREATING ARTHRITIC CONDITIONS USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
15/629678	US	6/21/2017	2017-0281597	10/5/2017	10092542	10/9/2018	Granted	Celgene Corporation	METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE
13/300458	US	11/18/2011	2012-0101144	4/26/2012	8629173	1/14/2014	Granted	Celgene Corporation	SOLID FORMS COMPRISING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE, COMPOSITIONS THEREOF, AND USES THEREOF
16/125571	US	9/7/2018	2019-0000804	1/3/2019			Pending	Celgene Corporation	METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE
14/316160	US	6/26/2014	2014-0371287 A1	12/18/2014	9283207	3/15/2016	Granted	Celgene Corporation	METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE
11/106142	US	4/13/2005	2005-0192336	9/1/2005	7427638	9/23/2008	Granted	Celgene Corporation	(+)-2-[1-(3-ETHOXY-4-METHOXYLPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE, AND METHODS OF USING AND COMPOSITIONS THEREOF

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
11/170308	US	6/28/2005	2005-0267196	12/1/2005	7358272	4/15/2008	Granted	Celgene Corporation	METHODS OF USING +2-[1-(3-ETHOXY-4-METHOXYLPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOINDOLINE-1,3-DIONE
11/392846	US	3/28/2006	2006-0183788	8/17/2006	7276529	10/2/2007	Granted	Celgene Corporation	METHODS OF TREATMENT OR PREVENTION OF EXERCISE-INDUCED ASTHMA USING +2-[1-3-ETHOXY-4-METHOXYLPHENYL]-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOINDOLINE-1,3-DIONE
11/392845	US	3/28/2006	2006-0183787	8/17/2006	7208516	4/24/2007	Granted	Celgene Corporation	METHODS OF THE TREATMENT OF PSORIATIC ARTHRITIS USING +2-[1-3-ETHOXY-4-METHOXYLPHENYL]-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOINDOLINE-1,3-DIONE
14/102407	US	12/10/2013	2014-0100259	4/10/2014	9018243	4/28/2015	Granted	Celgene Corporation	SOLID FORMS COMPRISING (+)-2-[1-(3-ETHOXY-4-METHOXYLPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOINDOLINE-1,3-DIONE, COMPOSITIONS THEREOF, AND USES THEREOF
11/824523	US	6/29/2007	2008-0027123	1/31/2008	7507759	3/24/2009	Granted	Celgene Corporation	METHODS OF USING +2-[1-(3-ETHOXY-4-METHOXYLPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOINDOLINE-1,3-DIONE

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
12/069,282	US	2/8/2008	2008-0207730	8/28/2008	7659302	2/9/2010	Granted	Celgene Corporation	METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYLPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOPYRIMIDIN-5(1H)-ONE
12/079615	US	3/27/2008	2008-0234359	9/25/2008	7893101	2/22/2011	Granted	Celgene Corporation	SOLID FORMS COMPRISING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOPYRIMIDIN-5(1H)-ONE
12/098379	US	4/4/2008	2008-0242719	10/2/2008	7659303	2/9/2010	Granted	Celgene Corporation	METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOPYRIMIDIN-5(1H)-ONE
14/670336	US	3/26/2015	2015-0196535	7/16/2015	9433606	9/6/2016	Granted	Celgene Corporation	SOLID FORMS COMPRISING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOPYRIMIDIN-5(1H)-ONE, COMPOSITIONS THEREOF, AND USES THEREOF
12/630788	US	12/3/2009	2010-0160405	6/24/2010	8455536	6/4/2013	Granted	Celgene Corporation	(+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOPYRIMIDIN-5(1H)-ONE, METHODS OF USING AND COMPOSITIONS THEREOF

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
10/798372	US	3/12/2004	2004-0259873	12/23/2004	6911464	6/28/2005	Granted	Celgene Corporation	N-ALKYL-HYDROXAMIC ACID-ISINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES
11/124280	US	5/9/2005	2005-0203090	9/15/2005	7662847	2/16/2010	Granted	Celgene Corporation	METHODS OF USING N-ALKYL-HYDROXAMIC ACID-ISINDOLYL COMPOUNDS
12/705527	US	2/12/2010	2010-0267800-A1	10/21/2010	8076369	12/13/2011	Abandoned	Celgene Corporation	N-ALKYL-HYDROXAMIC ACID-ISINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES
10/900,270	US	7/28/2004	2006-0084815	4/20/2006	7244759	7/17/2007	Abandoned	Celgene Corporation	ISINDOLINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
11/820,788	US	6/19/2007	244183	10/18/2007	7495112	2/24/2009	Granted	Celgene Corporation	ISINDOLINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
12/368,245	US	2/9/2009	2009-0148388-A1	6/11/2009	8026269	9/27/2011	Granted	Celgene Corporation	ISINDOLINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
10/900,332	US	7/28/2004	2006-0025457	2/2/2006	7405237	7/29/2008	Granted	Celgene Corporation	ISINDOLINE COMPOUNDS AND METHODS OF THEIR USE
12/070,322	US	2/15/2008	US-2008-0145336-A1	6/19/2008	7569597	8/4/2009	Granted	Celgene Corporation	ISINDOLINE COMPOUNDS AND METHODS OF THEIR USE
12/535,642	US	8/4/2009	20090291991A1	11/26/2009	7816393	10/19/2010	Granted	Celgene Corporation	ISINDOLINE COMPOUNDS AND METHODS OF THEIR USE
60/993,238	US	9/10/2007					Inactive	Celgene Corporation	PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS
61/095,902	US	9/10/2008					Inactive	Celgene Corporation	PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS
12/556479	US	9/9/2009	20100168475A1	7/1/2010	8242310	8/14/2012	Granted	Celgene Corporation	PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
61/259,903	US	11/10/2009					Inactive	Celgene Corporation	NANOSUSPENSION OF A POORLY SOLUBLE DRUG VIA MICROFLUIDIZATION PROCESS
12/942930	US	11/9/2010	2011-0124702	5/26/2011	9023886	5/5/2015	Granted	Celgene Corporation	NANOSUSPENSION OF A POORLY SOLUBLE DRUG VIA MICROFLUIDIZATION PROCESS
14/676709	US	4/1/2015	2015-0265534	9/24/2015	9616019	4/11/2017	Granted	Celgene Corporation	NANOSUSPENSION OF A POORLY SOLUBLE DRUG VIA MICROFLUIDIZATION PROCESS
61/355,116	US	6/15/2010					Inactive	Celgene Corporation	Biomarkers for the Treatment of Psoriasis
61/454916	US	3/21/2011					Inactive	Celgene Corporation	Biomarkers for the Treatment of Psoriasis
13/161201	US	6/15/2011	2011-0318741	12/29/2011			Pending	Celgene Corporation	Biomarkers for the Treatment of Psoriasis
61/449716	US	3/7/2011					Inactive	Celgene Corporation	METHODS FOR TREATING DISEASES USING AMIDOISINDOLINE COMPOUNDS
14/003750	US	2/19/2014	2014-0187599	7/3/2014	9387195	7/12/2016	Granted	Celgene Corporation	Methods for Treating Diseases Using Isoindoline Compounds
61/424003	US	12/16/2010					Inactive	Celgene Corporation	Controlled release oral dosage forms of poorly soluble drugs and uses thereof
14/938714	US	11/11/2015	2016-0128981	5/12/2016	9532977	1/3/2017	Granted	Celgene Corporation	Controlled release oral dosage forms of poorly soluble drugs and uses thereof
13/993046	US	10/2/2013	2014-0018404	1/16/2014			Abandoned	Celgene Corporation	Controlled release oral dosage forms of poorly soluble drugs and uses thereof
61/431,355	US	1/10/2011					Inactive	Celgene Corporation	Oral dosage forms of Cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
13/978869	US	12/19/2013	2014-0093561	4/3/2014	9757355	9/12/2017	Granted	Celgene Corporation	Oral dosage forms of Cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-indol-4-yl}-amide
61/431,350	US	1/10/2011					Inactive	Celgene Corporation	Pheylethylsulfone Isoindoline Derivatives and Their Use
13/346455	US	1/9/2012	2012-0178708	7/12/2012	8853175	10/7/2014	Granted	Celgene Corporation	Phenylethylsulfone Isoindoline Derivatives and Their Use
61/433123	US	1/14/2011					Inactive	Celgene Corporation	ISOTOPOLOGUES OF ISOINDOLINE DERIVATIVES
13/979602	US	2/26/2014	2014-0194485	7/10/2014	9045417	6/2/2015	Granted	Celgene Corporation	ISOTOPOLOGUES OF ISOINDOLINE DERIVATIVES
14/726287	US	5/29/2015	2015-0258063	9/17/2015	9642836	5/9/2017	Granted	Celgene Corporation	ISOTOPOLOGUES OF ISOINDOLINE DERIVATIVES
61/480,263	US	4/28/2011					Inactive	Celgene Corporation	METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
13/458896	US	4/27/2012	2012-0276087	11/1/2012	9272035	3/1/2016	Granted	Celgene Corporation	METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
61/534841	US	9/14/2011					Inactive	Celgene Corporation	FORMULATIONS OF CYCLOPROPANECARBOXYLIC ACID {2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-indol-4-yl}-amide

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
14/344870	US	1/20/2015	2015-0190374 A1	7/9/2015	9884042	2/6/2018	Granted	Celgene Corporation	FORMULATIONS OF CYCLOPROPANECARBOXYLIC ACID {2-(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHANESULFONYL-ETHYL]-3-OXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE
61/580626	US	12/27/2011					Inactive	Celgene Corporation	FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE
13/727366	US	12/26/2012	2013-0164376- A1	6/27/2013			Pending	Celgene Corporation	FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL]-4-ACETYLAMINOISINDOLINE-1,3-DIONE
61/601226	US	2/21/2012					Inactive	Celgene Corporation	SUBSTITUTED DIAMINOCARBOXAMIDE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
13/771164	US	2/20/2013	2013-0217918 A1	8/22/2013	9187417	11/17/2015	Granted	Celgene Corporation	PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE
14/882564	US	10/14/2015	2016-0031808	2/4/2016	9586897	3/7/2017	Granted	Celgene Corporation	PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE



Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
15/414782	US	1/25/2017	2017-0129852	5/11/2017	9688623	6/27/2017	Granted	Celgene Corporation	PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHANESULFONYLETHYL AMINE
61/601480	US	2/21/2012					Inactive	Celgene Corporation	ASYMMETRIC HYDROGENATION OF ENAMINE SUBSTRATE
61/648521	US	5/17/2012					Inactive	Celgene Corporation	ASYMMETRIC HYDROGENATION OF ENAMINE SUBSTRATE
13/772242	US	2/20/2013	2013-0217919	8/22/2013	9126906	9/8/2015	Granted	Celgene Corporation	ASYMMETRIC SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS
61/693112	US	8/24/2012					Inactive	Celgene Corporation	USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS
61/993467	US	5/15/2014					Inactive	Celgene Corporation	USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS
14/712595	US	5/14/2015	2015-0328187	11/19/2015	9480676	11/1/2016	Granted	Celgene Corporation	USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS
29/425538	US	6/25/2012			D735315	7/28/2015	Granted	Celgene Corporation	Pharmaceutical Tablet
61/701424	US	9/14/2012					Inactive	Celgene Corporation	PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
14/026794	US	9/13/2013	2014-0081032 A1	3/20/2014	8981117	3/17/2015	Granted	Celgene Corporation	PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF
14/642511	US	3/9/2015	2015-0183739	7/2/2015	9434689	9/6/2016	Granted	Celgene Corporation	PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF
61/782880	US	3/14/2013					Inactive	Celgene Corporation	METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS USING APREMILAST
14/209874	US	3/13/2014	2015-0174100- A2	6/25/2015	9872854	1/23/2018	Granted	Celgene Corporation	METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS USING APREMILAST
61/835667	US	6/17/2013					Inactive	Celgene Corporation	FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE
61/840210	US	6/27/2013					Inactive	Celgene Corporation	FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE
14/305082	US	6/16/2014	2014-0370092	12/18/2014	9468605	10/18/2016	Granted	Celgene Corporation	FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE
61/931143	US	1/24/2014					Inactive	Celgene Corporation	METHODS FOR THE TREATMENT OF OBESITY USING APREMILAST

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
14/603128	US	1/22/2015	2015-0209327	7/30/2015			Abandoned	Celgene Corporation	METHODS FOR THE TREATMENT OF OBESITY USING APREMILAST
61/994773	US	5/16/2014					Inactive	Celgene Corporation	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS
15/311153	US	11/14/2016	2017-0087129	3/30/2017			Pending	Celgene Corporation	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS
62/016013	US	6/23/2014					Inactive	Celgene Corporation	METHODS FOR THE TREATMENT OF LIVER DISEASE OR A LIVER FUNCTION ABNORMALITY USING APREMILAST
15/321718	US	12/22/2016	2017-0143671	5/25/2017	10300042	5/28/2019	Granted	Celgene Corporation	APREMILAST FOR THE TREATMENT OF A LIVER DISEASE OR A LIVER FUNCTION ABNORMALITY
62/038176	US	8/15/2014					Inactive	Celgene Corporation	METHODS FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION USING DOSAGE TITRATION OF APREMILAST
16/109634	US	8/22/2018	2018-0360807	12/20/2018			Pending	Celgene Corporation	METHODS FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION USING DOSAGE TITRATION OF APREMILAST
14/826027	US	8/13/2015	2016-0045475	2/18/2016	10092541	10/9/2018	Granted	Celgene Corporation	METHODS FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION USING DOSAGE TITRATION OF APREMILAST

Application No.	Country	Filing Date	Publication No.	Publication Date	Patent Number	Issue Date	Application Status	Assignee PTO Record	Title
62/237910	US	10/6/2015					Inactive	Celgene International II Sarl	METHODS FOR TREATING INFLAMMATORY AND OTHER DISEASES AND THE USE OF BIOMARKERS AS PREDICTORS OF CLINICAL SENSITIVITY TO TREATMENT WITH APREMILAST
62/237901	US	10/6/2015					Inactive	Celgene International II Sarl	METHODS FOR TREATING INFLAMMATORY AND OTHER DISEASES AND THE USE OF BIOMARKERS AS PREDICTORS OF CLINICAL SENSITIVITY TO TREATMENT WITH APREMILAST
15/286302	US	10/5/2016	2017-0097360	4/6/2017	10018637	7/10/2018	Granted	Celgene International II Sarl	METHODS FOR TREATING INFLAMMATORY AND OTHER DISEASES AND THE USE OF BIOMARKERS AS PREDICTORS OF CLINICAL SENSITIVITY TO TREATMENT WITH APREMILAST
61/321802	US	4/7/2010					Inactive	Celgene Corporation	METHODS FOR TREATING RESPIRATORY VIRAL INFECTION
61/435726	US	1/24/2011					Inactive	Celgene Corporation	METHODS FOR TREATING RESPIRATORY VIRAL INFECTION
13/639848	US	1/4/2013	2013-0136770 A1	5/30/2013	9408831	8/9/2016	Granted	Celgene Corporation	METHODS FOR TREATING RESPIRATORY VIRAL INFECTION
62/639650	US	3/7/2018					Inactive	Celgene Corporation	METHODS AND COMPOSITIONS OF ISINDOLINE-1,3-DIONE AND ISINDOLE PRODRUGS USEFUL FOR TREATING CANCER, ULCERATIVE COLITIS AND RELATED INFLAMMATORY DISEASES